Erratum: Recombinant human adenovirusp53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-FBXW7 pathway, which controls c-Myc and cyclin E (PLoS One(2013) 8:7 (e68574) DOI: 10.1371/journal.pone.0068574);Recombinant Human Adenovirus-p53 Injection Induced Apoptosis in Hepatocellular Carcinoma Cell Lines Mediated by p53-Fbxw7 Pathway, Which Controls c-Myc and Cyclin E

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Tu, Kangsheng ^a   Zheng, Xin ^a   Zhou, Zhenyu ^a   Li, Chao ^a   Zhang, Jing ^a   Gao, Jie ^a   Yao, Yingmin ^a   Liu, Qingguang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; FBXW7 PROTEIN; GENDICINE; MYC PROTEIN; PROTEASOME; PROTEIN P53; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; TUMOR GROWTH; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

HUMAN ADENOVIRUS; MURINAE;

EID: 84879711750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0231287     Document Type: Erratum

References (29)

1. Forner, Alejandro, Llovet Josep M, Bruix Jordi (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255. doi:10.1016/S0140-6736(11)61347-0. PubMed: 22353262.
2. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, et al. (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471: 110-114. doi:10.1038/nature09779. PubMed: 21368834.
3. Crusio KM, King B, Reavie LB, Aifantis I, (2010) The ubiquitous nature of cancer: the role of the SCF (Fbw7) complex in development and transformation. Oncogene 29: 4865-4873. doi:10.1038/onc.2010.222. PubMed: 20543859.
4. Wang Z, Fukushima H, Gao D, Inuzuka H, Wan L, et al. (2011) The two faces of FBW7 in cancer drug Resistance. Bioessays 33: 851-859. doi:10.1002/bies.201100101. PubMed: 22006825.
5. Tu K, Zheng X, Yin G, Zan X, Yao Y, et al. (2012) Evaluation of Fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD. Mol Med Report 6: 525-530.
6. Welcker M, Clurman BE, (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93. doi:10.1038/nrc2290. PubMed: 18094723.
7. Tu K, Zheng X, Zan X, Han S, Yao Y, et al. (2012) Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res 42: 904-910. doi:10.1111/j.1872-034X.2012.01005.x. PubMed: 22548670.
8. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, et al. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428. doi:10.1038/350427a0. PubMed: 1849234.
9. Piao Z, Kim H, Jeon BK, Lee WJ, Park C, (1997) Relationship beween loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 80: 865-872. doi:10.1002/(SICI)1097-0142(19970901)80:5. PubMed: 9307185.
10. Honda K, Sbisà E, Tullo A, Papeo PA, Saccone C, et al. (1998) p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 77: 776-782. doi:10.1038/bjc.1998.126. PubMed: 9514057.
11. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, et al. (2004) Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432: 775-779. doi:10.1038/nature03155. PubMed: 15592418.
12. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, et al. (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23: 2116-2125. doi:10.1038/sj.emboj.7600217. PubMed: 15103331.
13. Grandori C, Cowley SM, James LP, Eisenman RN, (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699. doi:10.1146/annurev.cellbio.16.1.653. PubMed: 11031250.
14. Hwang HC, Clurman BE, (2005) Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786. doi:10.1038/sj.onc.1208613. PubMed: 15838514.
15. Peng Z, (2005) Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16: 1016-1027. doi:10.1089/hum.2005.16.1016. PubMed: 16149900.
16. Xie Q, Liang BL, Wu YH, Zhang J, Chen MW, et al. (2012) Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. Gene 499: 303-308. doi:10.1016/j.gene.2012.02.007. PubMed: 22441128.
17. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, et al. (2007) FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67: 9006-9012. doi:10.1158/0008-5472.CAN-07-1320. PubMed: 17909001.
18. Bressac B, Kew M, Wands J, Ozturk M, (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431. doi:10.1038/350429a0. PubMed: 1672732.
19. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, et al. (1995) The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 22: 1702-1707. doi:10.1002/hep.1840220614. PubMed: 7489977.
20. Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z, et al. (2009) In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res 15: 6724-6731. doi:10.1158/1078-0432.CCR-09-1296. PubMed: 19861457.
21. Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, et al. (2005) Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol 98: 124-128. doi:10.1016/j.ygyno.2005.04.007. PubMed: 15913747.
22. Ibusuki M, Yamamoto Y, Shinriki S, Ando Y, Iwase H, (2011) Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci 102: 439-445. doi:10.1111/j.1349-7006.2010.01801.x. PubMed: 21134077.
23. Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, et al. (2010) Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer 126: 1828-1837. PubMed: 19739118.
24. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, et al. (2009) p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 69: 3788-3794. doi:10.1158/0008-5472.CAN-08-2846. PubMed: 19366810.
25. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M, (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15: 2612-2624. PubMed: 7739542.
26. Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, et al. (2012) Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 30: 1966-1973. doi:10.1200/JCO.2011.39.7661. PubMed: 22547598.
27. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, et al. (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413: 316-322. doi:10.1038/35095076. PubMed: 11565034.
28. Haupt S, Berger M, Goldberg Z, Haupt Y, (2003) Apoptosis- the p53 network. J Cell Sci 116: 4077-4085. doi:10.1242/jcs.00739. PubMed: 12972501.
29. Prendergast GC, (1999) Mechanisms of apoptosis by c-Myc. Oncogene 18: 2967-2987. doi:10.1038/sj.onc.1202727. PubMed: 10378693.